Neurodegenerative Biomarkers R&D
Neurodegenerative Diseases
Key Facts
About Firalis
Firalis is a privately-held, revenue-generating biotechnology company operating as a specialized Contract Research Organization (CRO) and diagnostic developer. Leveraging its strategic location in Europe's pharmaceutical hub and a unique network of clinical experts, the company focuses on translational biomarker science across inflammatory disorders, cardiovascular diseases, neurodegenerative conditions, and drug safety. Its business model combines fee-for-service biomarker research with internal diagnostic product development, supported by significant EU research grants and consortia leadership. The company's goal is to improve therapeutic decisions and reduce healthcare costs through validated biomarker-based tools.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed | Modulo Bio | Discovery |
| PBI-01207 | Phoenix Biotechnology | Pre-clinical |
| Therapeutic Target Discovery Platform | ValtedSeq | Discovery |
| Undisclosed Neurology Program(s) | Base4 | Preclinical |
| Platform Application for Neurodegenerative Diseases | ALTUCELL | Pre-clinical/Research |
| OGG1 Activator Program | Luciole Pharmaceuticals | Pre-clinical |
| Lysosome Biology Program | Talisman Therapeutics | Preclinical |
| Microglial Health Program | Talisman Therapeutics | Preclinical |
| HSF1 Activator Program | Sisu Pharma | Pre-clinical |
| Platform-derived candidates | VRG Therapeutics | Pre-clinical |
| Neurodegeneration Pipeline | Origenis | Preclinical |
| Enhanced Brain Delivery (EBD™) Platform | Acumen Pharmaceuticals | Preclinical |